Ezra Plexo Software

Ezra Plexo Software is a medical diagnostic application designed to enhance oncological workflows by enabling advanced viewing, manipulation, 3D visualization, and quantitative analysis of MR images, specifically aiding in the detection and characterization of lesions. Its methodology involves providing web-based access to DICOM-compliant tools for volumetric segmentation and measurement, with its performance validated through nonclinical testing against expert radiologist consensus, positioning it as a complementary aid for clinical decision-making.

Ezra Plexo Software is a medical diagnostic application developed to assist clinicians in oncological workflows by providing tools for viewing, manipulating, 3D-visualizing, and comparing Magnetic Resonance (MR) medical images. Its primary purpose is to help users confirm the absence or presence of lesions, enabling their evaluation, quantification, and documentation. The software, accessed via a web browser, allows radiologists to interact with volumetric MR data, perform volumetric segmentation of regions of interest, edit these segmentations, and derive quantitative measurements. It processes previously generated DICOM image files, making its functionality independent of the MR image acquisition equipment vendor. The system's methodology relies on providing radiologists with 2D and 3D visualization capabilities, manual segmentation, and 2D semi-automated segmentation specifically for MR prostate studies. It also offers tools for linear dimension and volume calculation. Performance of the Ezra Plexo Software was established through nonclinical software validation tests on 150 patient exams, using consensus ground truth from five U.S. board-certified expert radiologists. These tests demonstrated that the software performs as intended, is acceptable for clinical use, and does not introduce new safety or efficacy concerns. It is designed as a complementary tool, with the clinician retaining ultimate responsibility for diagnosis based on standard practices.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How does the performance of Ezra Plexo's semi-automated segmentation for MR prostate studies compare to manual segmentation by experienced radiologists in terms of accuracy and time efficiency?; What specific quantitative measurements (e.g., volume, diameter, signal intensity characteristics) can be derived from the segmented lesions, and how have these been validated against ground truth?; Given its web-browser access, what are the specific data security and patient privacy protocols implemented within Ezra Plexo Software, particularly concerning data transfer and storage?; How does the integration of Ezra Plexo Software into existing radiological workflows affect diagnostic turnaround time and inter-observer variability in lesion assessment?; Are there plans to expand the software's capabilities to include other imaging modalities (e.g., CT) or other anatomical regions for semi-automated segmentation, similar to its predicate device?